Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Debate

Set Alert for Pricing Debate

Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood

Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.

Policy Pricing Debate Legislation

Latest From Pricing Debate

White House Advisor Philipson Brings Industry-Aligned Views On Drug Value

Tomas Philipson, a University of Chicago professor and consultant to the pharmaceutical industry, is named to the White House Council of Economic Advisors.

Appointments Pricing Debate

Industry In The Middle: Merck's Frazier Takes A Stand, Trump Tweets Back

The US president made what seemed to be a retaliatory statement about high drug prices after Merck CEO Ken Frazier resigned from his jobs council.

Leadership Pricing Debate

Pooled Purchasing Is Poor Answer To Latin American Drug Pricing Worries, Says Industry

Pooled procurement will not fix problems relating to affordability and access to medicines in South America, says the US pharma industry association, PhRMA, in response to news that Mercosur trade bloc members will join forces to negotiate better prices for medicines.

BioPharmaceutical Emerging Markets

Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review

Company says that while FDA has focused on expediting approval of third and fourth generics, it has not done so for first generics and complex products.

Generic Drugs Review Pathway

More European Countries Agree To Swap Pricing Info And Negotiate Prices

Another alliance among EU countries to tackle high medicines prices is gathering pace. Eight countries are to soon start swapping pricing information and have agreed to join forces to negotiate more affordable prices.

Market Access Policy

Medicare Part D Premiums Dip As Rebates Grow Faster Than Drug Costs To Plans

News that premiums will be lower in 2018 aligns with President Trump's concern with lowering drug costs, Administration officials announce.

Pricing Debate Medicare

Delayed Medicines To Hit Irish Market, But Uncertainty Remains For Future

Nine new approved treatments that have faced delays in getting to Irish patients should hit the market this year, says the Health Service Executive. The innovative pharmaceutical industry welcomes the move but is calling for clear political direction on future processes.

Ireland Health Technology Assessment

Number One With A Bullet: Eylea Takes Top Spot In Medicare Part B Drugs

Regeneron’s Eylea is the new holder of the number one spot in Medicare Part B prescription drug payments. It is also the fastest growing entrant on the top-ten list tracked by MedPAC. That is a sign of great commercial success – but could be an uncomfortable spotlight.

Medicare Ophthalmic

UK Industry Rebates Could Make NICE Cost-Effectiveness Assessments Unnecessary

Roche has praised the flexibility of the UK’s Cancer Drugs Fund, but says NICE cost-effectiveness analysis would be unnecessary if industry rebates fed into a UK drugs budget.

Europe BioPharmaceutical
See All